NEWS - Zhuhai Beihai Biotech Co., Ltd.

Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)

2024-10-31
Beihai Biotech was awarded both the "VBEF AWARDS-MOST Innovative And Creative Products In Healthcare" and the "China Future Healthcare Rankings 2024-Top Biomedicine Companies"

2024-05-11
Beihai Biotechnology has won the Biotechnology Awards

2024-04-12
Beihai Biotech is listed on the PEdaily “2023 VENTURE 50” Life and Health Ranking

2024-01-18
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY™)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Listed Among "Top 100 High-Growth Enterprises in the Greater Bay Area 2023"

2023-11-09

Contact Information

Company address：Blg 2, No. 6366, Zhuhai Ave., Jinwan, Zhuhai, 519090, China
Tel：0756-6349669
Human resources contact：hr@bayhibiotech.com
Business cooperation contact：hjiang@bayhibiotech.com

: Wechat Official Account